Person-First Language May Mitigate Stigmatization in Lung Cancer Screening

Commentary
Video

Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.

It is crucial to use person-first language to reduce potential feelings of stigmatization around lung cancer diagnoses and ensure that patients are receiving equitable treatment across the board, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.

In a conversation with CancerNetwork®, Carter-Bawa, director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery and Innovation, spoke about the prominent factors that may contribute to the stigmatization of lung cancer and thereby impact an individual’s decision to screen for potential disease. For example, she described how the act of smoking may instill feelings of blame and shame surrounding a lung cancer diagnosis and stated that avoiding the use of terms such as “smoker” in clinical communication may mitigate this stigmatization.

Transcript:

The most prominent factor boils down to blame and shame around smoking. Whether it is an underlying tone or message toward an individual or, very frankly, a blatant use of language to blame someone in the context of lung cancer. To give you an example, a person’s diagnosed with lung cancer and shares a diagnosis with a friend. The immediate response from the friend is saying something like, "I didn’t know you smoked." Somehow that act of smoking equates to deserving a deadly disease like lung cancer.

The point is that hearing that someone has lung cancer somehow automatically spurs the response that equates to blaming them for having the disease. This kind of public discourse around lung cancer has seeped into not just individuals diagnosed with lung cancer but backing it up to lung cancer screening with the same shame and blame feelings. Those are the prominent factors that contribute to feeling stigmatized.

I would love for my colleagues to take away envisioning a world where stigma in lung cancer doesn’t exist—that it’s just a historical blip that we look back on—and that we are treating people equitably across the board. [Where] we’re using person-first language and not referring to people as smoker and non-smoker in our scientific communication, our medical communication, or layman communications. That’s the biggest thing I would like colleagues to take away from this.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Related Content